# OnCo record targeted-therapy-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/targeted-therapy-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "targeted-therapy-roadmap" ;
  schema:name "Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall"@en ;
  schema:description "Targeted drugs switch off the specific broken protein a cancer depends on. The first ones turned a leukaemia into a chronic condition; the field then learned that resistance is the rule, designed drugs around it, and has now reached the drivers that were called impossible to target."@en ;
  schema:url <https://onco.cc/roadmaps/targeted-therapy-roadmap/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.nejm.org/doi/full/10.1056/NEJM200104053441401> ;
  onco:related <https://onco.cc/roadmaps/kras-roadmap/>, <https://onco.cc/roadmaps/hormonal-therapy-roadmap/>, <https://onco.cc/roadmaps/epigenetics-roadmap/>, <https://onco.cc/ideas/idea-bio1-ctdna-adaptive-tki/>, <https://onco.cc/ideas/idea-tr2-resistance-mechanism-baskets/>, <https://onco.cc/ideas/idea-bio1-resistance-platform-trial/>, <https://onco.cc/ideas/idea-bio1-evolution-forecasting/>, <https://onco.cc/ideas/idea-bio1-adaptive-therapy-platform/>, <https://onco.cc/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/>, <https://onco.cc/ideas/idea-bio1-resistance-mutation-vaccine/>, <https://onco.cc/drugs/eprenetapopt/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/drugs/mrtx1133/>, <https://onco.cc/roadmaps/lung-cancer-evidence-roadmap/>, <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/molecular-glue-platforms/>, <https://onco.cc/technologies/degrader-antibody-conjugate/>, <https://onco.cc/technologies/synthetic-lethality-approaches/>, <https://onco.cc/technologies/antisense-sirna/>, <https://onco.cc/technologies/de-novo-protein-design/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/prmt5-mtap/>, <https://onco.cc/targets/btk/>, <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/neladalkib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/vepdegestrant/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/eli-002-7p/> ;
  onco:companies <https://onco.cc/companies/nuvalent/>, <https://onco.cc/companies/frontier-medicines/>, <https://onco.cc/companies/black-diamond-therapeutics/> ;
  onco:institutions <https://onco.cc/institutions/ohsu-knight/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/hera-b31-n9831/>, <https://onco.cc/trials/toga/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/trials/mariposa/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/alina/>, <https://onco.cc/trials/laura/>, <https://onco.cc/trials/alkove-1/>, <https://onco.cc/trials/combi-ad/>, <https://onco.cc/trials/dreamseq/>, <https://onco.cc/trials/solo-1/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/profound/>, <https://onco.cc/trials/libretto-431/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/krystal-12/>, <https://onco.cc/trials/krascendo-1/>, <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/trials/litespark-005/>, <https://onco.cc/trials/veritac-2/>, <https://onco.cc/trials/cadance-304/>, <https://onco.cc/trials/bruin-cll-321/>, <https://onco.cc/trials/serena-6/>, <https://onco.cc/trials/insight-gist/>, <https://onco.cc/trials/telimet-nsclc-01/>, <https://onco.cc/trials/gefitinib-chemo-tmh/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-combination-space/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> .